MMX™ Multi Matrix System Presentation

Disclaimer

2

Important Notice



For the use of the recipient only. Not to be copied or distributed to any other person. This presentation has been prepared from publicly available information, internally developed data and other sources believed to be reliable. No representation, warranty or undertaking (express or implied) is given and no responsibility is accepted by Cosmo or by any of its officers, employees or agents for the completeness or accuracy of any information contained in, or of any omissions from, this presentation or any supplementary information made available to any interested party or its advisers, and any liability in respect of such information or omissions is hereby expressly disclaimed.



This presentation does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities or a solicitation of any such offer or invitation and shall not form the basis of any contract with Cosmo. Opinions expressed herein are subject to change without notice. In providing this presentation, Cosmo undertakes no obligation to provide the recipient with access to any further information or to correct any inaccuracies or omissions which may become apparent.

3

Drug Delivery Platform

    New oral delivery technology Designed for off-patent drugs Focus on inflammatory bowel diseases Scaleable/low cost of goods

The Drug Delivery Platform

Multi Matrix System™ (MMX ™) Inert matrix

4

Hydrophilic matrix Gastroprotectant layer HV hydrophilic polym. matrix drug (+ excipient) LV hydrophilic - amphipatic polymer matrix inert matrix material

MMX™ - Release of active ingredient

%

stomach Duodenum Dejunum Ileum

Colon 5 Time

IBD medications: sites of action MMX™ tablets vs. other dosage forms

Site of action 6

Oral dosage forms enemas

MMX ™ tablets

1h 30’ small intestine 3h 30’ ileum 4h 30’ ascending colon 7h 30’ trasverse colon

7

10h trasverse colon 15h descending colon

MMX™

8 16h descending colon 24h rectum

MMX™

Low absorption after single dose administration in Drug (•) and Metabolite (o)

I

I

10000

SI

IL

AC TC DC SC

1000

9

100 10 1 0 2 4 6 8 10 12 Time (h) 14 16 18 20 22 24